|
1.
|
|
9 p, 1.5 MB |
Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain
/
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Álvarez, Rosa (Hospital Gregorio Marañón (Madrid)) ;
Ortega, Ana Laura (Hospital Universitario de Jaén) ;
de Alda, Lucía Ruiz (Roche Farma) ;
Gordo, Rocío (Roche Farma) ;
García, J.Francisco (Roche Farma) ;
Ivanova-Markova, Yoana (Weber) ;
González-Domínguez, Almudena (Weber) ;
San Cristóbal, Raquel Sánchez (Weber) ;
Rojo, Federico (Hospital Universitario Fundación Jiménez Díaz) ;
Universitat Autònoma de Barcelona
In recent years, target therapies to specific molecular alterations in advanced non-small cell lung cancer (NSCLC) have been identified and have shown superior efficacy compared to non-targeted treatments. [...]
2022 -  10.33393/GRHTA.2022.2449
Global and Regional Health Technology Assessment, Vol. 9 (january 2022) , p. 82-90
|
|
|
2.
|
|
13 p, 254.2 KB |
Patient-Related Benefits for Adults with Cochlear Implantation : A Multicultural Longitudinal Observational Study
/
Lenarz, Thomas (Medizinische Hochschule Hannover) ;
Muller, Lida (Tygerberg Hospital) ;
Czerniejewska-Wolska, Hanna (Poznań University of Medical Sciences) ;
Varela, Hector Vallés (Hospital Clinico Universitario Lozano Blesa) ;
Orús Dotú, César (Institut d'Investigació Biomèdica Sant Pau) ;
Durko, Marcin (Barlicki University Hospital) ;
Irujo, Alicia Huarte (Clinica Universitaria de Navarra) ;
Piszczatowski, Bartosz (Medical University of Bialystok) ;
Zadrożniak, Marek (Medical University of Lublin) ;
Irwin, Colin (Cochlear AG) ;
Graham, Petra L. (Macquarie University) ;
Wyss, Josie (Cochlear AG) ;
Universitat Autònoma de Barcelona
To assess subjectively perceived, real-world benefits longitudinally for unilateral cochlear implant (CI) recipients in a multinational population treated routinely. To identify possible predictors of self-reported benefits. [...]
2017 - 10.1159/000477533
Audiology and Neurotology, Vol. 22 Núm. 2 (january 2017) , p. 61-73
|
|
|
3.
|
|
25 p, 1.7 MB |
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
/
O'Brien, Susan (University of California) ;
Hillmen, Peter (St. James University Hospital) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Barr, Paul M (University of Rochester Cancer Center) ;
Fraser, Graeme (McMaster University (Canadà)) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Burger, Jan A. (University of Texas MD Anderson Cancer Center) ;
Dilhuydy, Marie-Sarah (Centre Hospitalier Universitaire Hopitaux de Bordeaux) ;
Hess, Georg (Universitats Medizin Mainz) ;
Moreno Atanasio, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Cramer, Paula (University of Cologne) ;
Liu, Emily (Pharmacyclics LLC. an AbbVie Company) ;
Chang, Stephen (Pharmacyclics LLC. an AbbVie Company) ;
Vermeulen, Jessica (Janssen Research & Development) ;
Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ;
Howes, Angela (Janssen Research & Development) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Patel, Kalpesh (Janssen Pharmaceuticals. Inc) ;
Graef, Thorsten (Pharmacyclics LLC. an AbbVie Company) ;
Valentino, Rudolph (Pharmacyclics LLC. an AbbVie Company) ;
Universitat Autònoma de Barcelona
Ibrutinib, a Bruton's tyrosine kinase inhibitor, has become a standard treatment for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The present pooled safety analysis of 4 randomized controlled studies demonstrated a favorable benefit/risk profile for ibrutinib in patients with CLL/SLL and mantle cell lymphoma. [...]
2018 - 10.1016/j.clml.2018.06.016
Clinical Lymphoma, Myeloma & Leukemia, Vol. 18 Núm. 10 (october 2018) , p. 648-657.e15
|
|
|
4.
|
|
24 p, 1.1 MB |
Highlights from the 2019 International Aspirin Foundation Scientific Conference, Rome, 28 June 2019 : Benefits and risks of antithrombotic therapy for cardiovascular disease prevention
/
Walker, Jaqui (International Aspirin Foundation) ;
Cattaneo, Marco (Università degli studi di Milano) ;
Badimon, Lina (Institut d'Investigació Biomèdica Sant Pau) ;
Agnelli, Giancarlo (University of Perugia) ;
Chan, Andrew T. (Harvard Medical School) ;
Lanas, Angel (Universidad de Zaragoza) ;
Rocca, Bianca (Catholic University School of Medicine) ;
Rothwell, Peter (Centre for the Prevention of Stroke and Dementia) ;
Patrignani, Paola ('G.d'Annunizio' University) ;
Langley, Ruth (MRC Clinical Trials Unit at UCL) ;
Vilahur, Gemma (Institut d'Investigació Biomèdica Sant Pau) ;
Cosentino, Francesco (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Universitat Autònoma de Barcelona
At the 2019 International Aspirin Foundation Scientific Conference 'Benefits and Risks of Antithrombotic Therapy for Cardiovascular Disease Prevention', held in Rome, Italy, international experts sought to discuss and debate the optimal antithrombotic strategy for the secondary prevention of cardiovascular disease (CVD) and to seek agreement around dosing and target populations for aspirin use in primary disease prevention. [...]
2020 - 10.3332/ECANCER.2019.998
ecancermedicalscience, Vol. 14 (13 2020) , p. 998
|
|
|
5.
|
|
7 p, 259.9 KB |
Cost-effectiveness of a programme to address sedentary behaviour in older adults : Results from the SITLESS RCT
/
Deidda, Manuela (Health Economics and Health Technology Assessment (HEHTA). Institute of Health and Wellbeing (IHW). University of Glasgow) ;
Coll-Planas, Laura (Universitat Autònoma de Barcelona. Fundació Salut i Envelliment) ;
Tully, Marl A. (University of Ulster) ;
Giné-Garriga, Maria (Facultat de Psicologia i Ciències de l'Educació i de l'Esport Blanquerna) ;
Kee, Frank (UKCRC Centre of Excellence for Public Health (NI). Centre for Public Health. School of Medicine. Dentistry and Biomedical Sciences. Queen's University Belfast) ;
Roqué i Figuls, Marta (Institut d'Investigació Biomèdica Sant Pau) ;
Blackburn, Nicole E.. (University of Ulster) ;
Guerra-Balic, Míriam (Facultat de Psicologia i Ciències de l'Educació i de l'Esport Blanquerna) ;
Rothenbacher, Dietrich (Institute of Epidemiology and Medical Biometry. Ulm University) ;
Dallmeier, Dhayana (Agaplesion Bethesda Hospital. Geriatric Research Unit. Ulm University) ;
Caserotti, Paolo (Department of Sports Science and Clinical Biomechanics. Syddansk Universitet) ;
Skjødt, Mathias (Department of Sports Science and Clinical Biomechanics. Syddansk Universitet) ;
McIntosh, Emma (Health Economics and Health Technology Assessment (HEHTA). Institute of Health and Wellbeing (IHW). University of Glasgow) ;
Universitat Autònoma de Barcelona
Background: This study details the within-trial economic evaluation and long-term economic model of SITLESS, a multi-country, three-armed randomized controlled trial comparing a combined intervention of exercise referral schemes (ERS) enhanced by self-management strategies (SMS) against ERS alone and usual care (UC). [...]
2022 - 10.1093/eurpub/ckac017
European journal of public health, Vol. 32 Núm. 3 (january 2022) , p. 415-421
|
|
|
6.
|
|
11 p, 1.1 MB |
Safety of cladribine tablets in the treatment of patients with multiple sclerosis : An integrated analysis
/
Cook, Stuart (Rutgers. The State University of New Jersey) ;
Leist, Thomas (Jefferson University) ;
Comi, Giancarlo (Università Vita-Salute San Raffaele) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron) ;
Giovannoni, Gavin (Queen Mary University of London) ;
Nolting, Axel (Merck KGaA) ;
Hicking, Christine (Merck KGaA) ;
Galazka, Andrew (Merck. Zone Industrielle de L'Ouriettaz) ;
Sylvester, Elke (Merck KGaA) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Background: Treating patients with relapsing multiple sclerosis (MS) with cladribine tablets (two times 4 or 5 days of treatment each year for 2 years) results in long-lasting efficacy, with continued stability in many patients for 4 or more years. [...]
2019 - 10.1016/j.msard.2018.11.021
Multiple Sclerosis and Related Disorders, Vol. 29 (april 2019) , p. 157-167
|
|
|
7.
|
|
18 p, 951.7 KB |
Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis : A Network Meta-Analysis
/
Armstrong, April W (Department of Dermatology. Keck School of Medicine. University of Southern California) ;
Soliman, A.M. (AbbVie. Inc.) ;
Betts, Keith A (Analysis Group. Inc.) ;
Wang, Y. (Analysis Group. Inc.) ;
Gao, Y. (Analysis Group. Inc.) ;
Stakias, V. (AbbVie. Inc.) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
Introduction: The long-term benefit-risk profiles of licensed and investigational treatments for moderate-to-severe plaque psoriasis have not been fully characterized. Methods: Randomized controlled trials (RCTs) of licensed and investigational treatments for moderate-to-severe plaque psoriasis were identified through a systematic literature review through 2 May 2021. [...]
2022 - 10.1007/s13555-021-00647-0
Dermatology and Therapy, Vol. 12 Núm. 1 (january 2022) , p. 167-184
|
|
|
8.
|
|
|
9.
|
|
22 p, 567.8 KB |
Presupuestos y legislación con perspectiva de género : educación 0 a 3, permisos por nacimiento, jornadas y condiciones laborales
/
Castellanos Serrano, Cristina (Universidad Nacional de Educación a Distancia (Espanya)) ;
Perondi, Ana Carolina (Cámara de Comercio de España. Servicio de Estudios)
La educación infantil de 0 a 3 años es una política con efectos muy relevantes en el bienestar infantil y la igualdad de género. Su acceso universal es clave para garantizar la igualdad de oportunidades y tiene efectos positivos cuando es de calidad en el corto, medio y largo plazo en toda la infancia, especialmente en la de origen vulnerable. [...]
L'educació infantil de 0 a 3 anys és una política amb efectes molt rellevants en el benestar infantil i la igualtat de gènere. L'accés universal és clau per garantir la igualtat d'oportunitats i té efectes positius quan és de qualitat en els terminis curt, mitjà i llarg en tota la infància, especialment en la d'origen vulnerable. [...]
Education for 0 to 3-year-olds is a policy area with very significant effects on child wellbeing and gender equality. Universal access to childhood education is a key factor in guaranteeing equal opportunities; when it is of high quality, it has positive effects in the short, medium and long term for all children, especially those from vulnerable backgrounds. [...]
La educación infantil de 0 a 3 años es una política con efectos muy relevantes en el bienestar infantil y la igualdad de género. Su acceso universal es clave para garantizar la igualdad de oportunidades y tiene efectos positivos cuando es de calidad en el corto, medio y largo plazo en toda la infancia, especialmente en la de origen vulnerable. [...]
2022 - 10.5565/rev/papers.3064
Papers : revista de sociologia, Vol. 107 Núm. 3 (2022) , p. e3064 (Artículos de monográfico)
|
|
|
10.
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
